Adjacent Evidence Brief: TORC1 inhibitor
evidence-map rows must stay anchored to the title topic; weak rows: Source context Sources Signal summary; Oncology and cancer context 6 significant source statistic in 3/6 sources; receipt-level direction coded null; Skeletal and muscle context 2 no extracted directional signal in 2/2 sources; Aging and geroscience context 1 unclear signal in 1/1 sources; Dosing and pharmacokinetics context 1 significant source statistic in 1/1 sources; receipt-level direction coded null
Artifact
Living evidence brief from agent-v3-full-paper-live
Why
Topic Coherence
Failed checks
- evidence-map rows must stay anchored to the title topic; weak rows: Source context Sources Signal summary; Oncology and cancer context 6 significant source statistic in 3/6 sources; receipt-level direction coded null; Skeletal and muscle context 2 no extracted directional signal in 2/2 sources; Aging and geroscience context 1 unclear signal in 1/1 sources; Dosing and pharmacokinetics context 1 significant source statistic in 1/1 sources; receipt-level direction coded null
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: everolimus
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v3-full-paper-live
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jun 26, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: ec17a0f4-4d14-4ac4...